Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Objective</h3><p>Genetic variants in the <i>GRIN</i> genes that encode N-methyl-D-aspartate receptor (NMDAR) subunits have been identified in various neurodevelopmental disorders, including epilepsy. We identified a <i>GRIN1</i> variant from an individual with early-onset epileptic encephalopathy, evaluated functional changes to NMDAR properties caused by the variant, and screened FDA-approved therapeutic compounds as potential treatments for the patient. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>Whole exome sequencing identified a missense variant in <i>GRIN1</i>. Electrophysiological recordings were made from <i>Xenopus</i> oocytes and transfected HEK cells to determine the NMDAR biophysical properties as well as the sensitivity to agonists and FDA-approved drugs that inhibit NMDARs. A beta-lactamase reporter assay in transfected HEK cells evaluated the effects of the variant on the NMDAR surface expression. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>A recurrent de novo missense variant in <i>GRIN1</i> (c.1923G>A, p.Met641Ile), which encodes the GluN1 subunit, was identified in a pediatric patient with drug-resistant seizures and early-onset epileptic encephalopathy. In vitro analysis indicates that GluN1-M641I containing NMDARs showed enhanced agonist potency and reduced Mg<sup>2+</sup> block, which may be associated with the patient's phenotype. Results from screening FDA-approved drugs suggested that GluN1-M641I containing NMDARs are more sensitive to the NMDAR channel blockers memantine, ketamine, and dextromethorphan compared to the wild-type receptors. The addition of memantine to the seizure treatment regimen significantly reduced the patient's seizure burden. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Interpretation</h3><p>Our finding contributes to the understanding of the phenotype–genotype correlations of patients with <i>GRIN1</i> gene variants, provides a molecular mechanism underlying the actions of this variant, and explores therapeutic strategies for treating <i>GRIN1</i>-related neurological conditions. </p></section>

Heterogeneous Clinical and Functional Features of GRIN2D-related Developmental and Epileptic Encephalopathy.

Neurobiology of Disease Subunit Susceptibility Variants E 177 A and R 220 H Associated with Complex Epilepsy Alter Channel Gating and Surface Expression of 4 2 GABAA Receptors

Disease-Associated Variants in GRIN1, GRIN2A and GRIN2B genes: Insights into NMDA Receptor Structure, Function, and Pathophysiology

Differential functional consequences of GRIN2A mutations associated with schizophrenia and neurodevelopmental disorders

De novo GRIN variants in M3 helix associated with neurological disorders control channel gating of NMDA receptor

GRIN1 variants associated with neurodevelopmental disorders reveal channel gating pathomechanisms

GRIN2B encephalopathy: novel findings on phenotype, variant clustering, functional consequences and treatment aspects

A De Novo Loss-of-function GRIN2A Mutation Associated with Childhood Focal Epilepsy and Acquired Epileptic Aphasia.

GRIN2A Variants Associated with Idiopathic Generalized Epilepsies.

De novo GRIN2A variants associated with epilepsy and autism and literature review

Functional Investigation of a GRIN2A Variant Associated with Rolandic Epilepsy

Recurrent seizure‐related GRIN1 variant: Molecular mechanism and targeted therapy

Clinical and Therapeutic Significance of Genetic Variation in the GRIN Gene Family Encoding NMDARs

Differential responses of disease-related GRIN variants located in pore-forming M2 domain of N-methyl-D-aspartate receptor to FDA-approved inhibitors

De Novo Mutations and Rare Variants Occurring in NMDA Receptors.

Characterization of Mice Carrying a Neurodevelopmental Disease-Associated GluN2B(L825V) Variant

N-terminal alternative splicing of GluN1 regulates the maturation of excitatory synapses and seizure susceptibility.

Disease-associated missense mutations in GluN2B subunit alter NMDA receptor ligand binding and ion channel properties

Grin1 Y 647 S/+ Mice: A Preclinical Model of GRIN1 -Related Neurodevelopmental Disorder

[Neurodevelopmental disorders associated with variants of GRIN gene family].

Grin1Y647S/+ Mice: A Preclinical Model of GRIN1-Related Neurodevelopmental Disorder